| Report ID | 276002 |
| Drug Identification Number | 02139502 |
| Brand name | VASOPRESSIN INJECTION, USP |
| Common or Proper name | VASOPRESSIN INJECTION, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | VASOPRESSIN |
| Strength(s) | 20UNIT |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS INTRAMUSCULAR SUBCUTANEOUS INTRAMUSCULAR |
| Packaging size | 1 mL |
| ATC code | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2026-02-01 |
| Actual start date | |
| Estimated end date | 2026-03-31 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2026-01-14 |
| Company comments | Due to production delays, allocations for our Vasopressin Injection, USP 20 USP units/mL, 1 mL Vial, will be reduced effective February 1, 2026. Customers will be allocated 50% of historical monthly demand. Effective March 1, 2026, until March 31, 2026, we will encounter a backorder on this product. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2026-01-14 | French | Compare |
| v1 | 2026-01-14 | English | Compare |
Showing 1 to 2 of 2